168 related articles for article (PubMed ID: 35039091)
1. Meeting report: the 2021 FSHD International Research Congress.
Jagannathan S; de Greef JC; Hayward LJ; Yokomori K; Gabellini D; Mul K; Sacconi S; Arjomand J; Kinoshita J; Harper SQ
Skelet Muscle; 2022 Jan; 12(1):1. PubMed ID: 35039091
[TBL] [Abstract][Full Text] [Related]
2. Transgenic mice expressing tunable levels of DUX4 develop characteristic facioscapulohumeral muscular dystrophy-like pathophysiology ranging in severity.
Jones TI; Chew GL; Barraza-Flores P; Schreier S; Ramirez M; Wuebbles RD; Burkin DJ; Bradley RK; Jones PL
Skelet Muscle; 2020 Apr; 10(1):8. PubMed ID: 32278354
[TBL] [Abstract][Full Text] [Related]
3. Facioscapulohumeral muscular dystrophy family studies of DUX4 expression: evidence for disease modifiers and a quantitative model of pathogenesis.
Jones TI; Chen JC; Rahimov F; Homma S; Arashiro P; Beermann ML; King OD; Miller JB; Kunkel LM; Emerson CP; Wagner KR; Jones PL
Hum Mol Genet; 2012 Oct; 21(20):4419-30. PubMed ID: 22798623
[TBL] [Abstract][Full Text] [Related]
4. Single-cell RNA sequencing in facioscapulohumeral muscular dystrophy disease etiology and development.
van den Heuvel A; Mahfouz A; Kloet SL; Balog J; van Engelen BGM; Tawil R; Tapscott SJ; van der Maarel SM
Hum Mol Genet; 2019 Apr; 28(7):1064-1075. PubMed ID: 30445587
[TBL] [Abstract][Full Text] [Related]
5. Protein kinase A activation inhibits
Cruz JM; Hupper N; Wilson LS; Concannon JB; Wang Y; Oberhauser B; Patora-Komisarska K; Zhang Y; Glass DJ; Trendelenburg AU; Clarke BA
J Biol Chem; 2018 Jul; 293(30):11837-11849. PubMed ID: 29899111
[TBL] [Abstract][Full Text] [Related]
6. Facioscapulohumeral dystrophy: activating an early embryonic transcriptional program in human skeletal muscle.
Campbell AE; Belleville AE; Resnick R; Shadle SC; Tapscott SJ
Hum Mol Genet; 2018 Aug; 27(R2):R153-R162. PubMed ID: 29718206
[TBL] [Abstract][Full Text] [Related]
7. DUX4 Signalling in the Pathogenesis of Facioscapulohumeral Muscular Dystrophy.
Lim KRQ; Nguyen Q; Yokota T
Int J Mol Sci; 2020 Jan; 21(3):. PubMed ID: 31979100
[TBL] [Abstract][Full Text] [Related]
8. A complex interplay of genetic and epigenetic events leads to abnormal expression of the DUX4 gene in facioscapulohumeral muscular dystrophy.
Gatica LV; Rosa AL
Neuromuscul Disord; 2016 Dec; 26(12):844-852. PubMed ID: 27816329
[TBL] [Abstract][Full Text] [Related]
9. The Genetics and Epigenetics of Facioscapulohumeral Muscular Dystrophy.
Himeda CL; Jones PL
Annu Rev Genomics Hum Genet; 2019 Aug; 20():265-291. PubMed ID: 31018108
[TBL] [Abstract][Full Text] [Related]
10. p38
Rojas LA; Valentine E; Accorsi A; Maglio J; Shen N; Robertson A; Kazmirski S; Rahl P; Tawil R; Cadavid D; Thompson LA; Ronco L; Chang AN; Cacace AM; Wallace O
J Pharmacol Exp Ther; 2020 Sep; 374(3):489-498. PubMed ID: 32576599
[TBL] [Abstract][Full Text] [Related]
11. Overexpression of the double homeodomain protein DUX4c interferes with myofibrillogenesis and induces clustering of myonuclei.
Vanderplanck C; Tassin A; Ansseau E; Charron S; Wauters A; Lancelot C; Vancutsem K; Laoudj-Chenivesse D; Belayew A; Coppée F
Skelet Muscle; 2018 Jan; 8(1):2. PubMed ID: 29329560
[TBL] [Abstract][Full Text] [Related]
12. Facioscapulohumeral muscular dystrophy: the road to targeted therapies.
Tihaya MS; Mul K; Balog J; de Greef JC; Tapscott SJ; Tawil R; Statland JM; van der Maarel SM
Nat Rev Neurol; 2023 Feb; 19(2):91-108. PubMed ID: 36627512
[TBL] [Abstract][Full Text] [Related]
13. Muscle pathology from stochastic low level DUX4 expression in an FSHD mouse model.
Bosnakovski D; Chan SSK; Recht OO; Hartweck LM; Gustafson CJ; Athman LL; Lowe DA; Kyba M
Nat Commun; 2017 Sep; 8(1):550. PubMed ID: 28916757
[TBL] [Abstract][Full Text] [Related]
14. Clinically Advanced p38 Inhibitors Suppress DUX4 Expression in Cellular and Animal Models of Facioscapulohumeral Muscular Dystrophy.
Oliva J; Galasinski S; Richey A; Campbell AE; Meyers MJ; Modi N; Zhong JW; Tawil R; Tapscott SJ; Sverdrup FM
J Pharmacol Exp Ther; 2019 Aug; 370(2):219-230. PubMed ID: 31189728
[TBL] [Abstract][Full Text] [Related]
15. RNA interference inhibits DUX4-induced muscle toxicity in vivo: implications for a targeted FSHD therapy.
Wallace LM; Liu J; Domire JS; Garwick-Coppens SE; Guckes SM; Mendell JR; Flanigan KM; Harper SQ
Mol Ther; 2012 Jul; 20(7):1417-23. PubMed ID: 22508491
[TBL] [Abstract][Full Text] [Related]
16. Muscle xenografts reproduce key molecular features of facioscapulohumeral muscular dystrophy.
Mueller AL; O'Neill A; Jones TI; Llach A; Rojas LA; Sakellariou P; Stadler G; Wright WE; Eyerman D; Jones PL; Bloch RJ
Exp Neurol; 2019 Oct; 320():113011. PubMed ID: 31306642
[TBL] [Abstract][Full Text] [Related]
17. Expression of DUX4 in zebrafish development recapitulates facioscapulohumeral muscular dystrophy.
Mitsuhashi H; Mitsuhashi S; Lynn-Jones T; Kawahara G; Kunkel LM
Hum Mol Genet; 2013 Feb; 22(3):568-77. PubMed ID: 23108159
[TBL] [Abstract][Full Text] [Related]
18. PAX7 target gene repression is a superior FSHD biomarker than DUX4 target gene activation, associating with pathological severity and identifying FSHD at the single-cell level.
Banerji CRS; Zammit PS
Hum Mol Genet; 2019 Jul; 28(13):2224-2236. PubMed ID: 31067297
[TBL] [Abstract][Full Text] [Related]
19. Outcome Measures in Facioscapulohumeral Muscular Dystrophy Clinical Trials.
Ghasemi M; Emerson CP; Hayward LJ
Cells; 2022 Feb; 11(4):. PubMed ID: 35203336
[TBL] [Abstract][Full Text] [Related]
20. DUX4-induced constitutive DNA damage and oxidative stress contribute to aberrant differentiation of myoblasts from FSHD patients.
Dmitriev P; Bou Saada Y; Dib C; Ansseau E; Barat A; Hamade A; Dessen P; Robert T; Lazar V; Louzada RAN; Dupuy C; Zakharova V; Carnac G; Lipinski M; Vassetzky YS
Free Radic Biol Med; 2016 Oct; 99():244-258. PubMed ID: 27519269
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
